News & Media
Building on the success of EBD Group’s flagship conference, BIO-Europe®, BIO-Europe Spring will bring together more than 3,700 top executives from around the world. More than 20,000 meetings of potential partnerships will take place to connect leaders in academia, start-ups and growing biotechnology companies with forward-looking investors and pharmaceutical companies.
- Evento
È stato siglato un accordo con NewCap, società francese di Investor Relation, la quale si occuperà della gestione delle comunicazioni ufficiali di BIOGENERA SpA a partire dalla quotazione in borsa su Euronext di Parigi.
- Corporate Update
The congress was attended by more than 800 researchers from around the World. Preclinical data of BIOGENERA’s new anti-tumor drug BGA002 were presented, and the new Phase I clinical trial for Neuroblastoma that will be initiated in the coming months was also presented. The data attracted great interest and attention.
- Evento
Il 2 Maggio 2023 l’assemblea dei soci di BIOGENERA ha approvato il bilancio 2022, in questa occasione è stato anche nominato il nuovo Consiglio di Amministrazione (CdA). Il Dott. Thibaud Eckenschwiller è stato nominato Presidente del CdA di BIOGENERA. Il Dott. Eckenschwiller è top manager del settore farmaceutico con ampia esperienza internazionale.
- Corporate Update
Dr. Giacinto d’Ettorre has been appointed as a new board member of BIOGENERA. Dr. D’Ettorre has many years of experience in the pharmaceutical industry at management levels. He currently serves as chief financial officer (CFO) at a leading pharmaceutical company, and previously served as CFO of Europe at SHIRE (now merged into TAKEDA), and CFO of Brazil for ROCHE.
- Corporate Update
Regarding patents held by BIOGENERA, a patent has been granted outright in Argentina. This brings to a total of 56 fully-owned BIOGENERA patents that are approved outright, covering 46 countries globally, covering the MyGeneraTM platform, the drug BGA002 and five other drug candidates.
- Research
English 
Italian